AstraZeneca PLC (AZN)vsOmada Health, Inc. Common Stock (OMDA)
AZN
AstraZeneca PLC
$182.85
+0.18%
HEALTHCARE · Cap: $286.68B
OMDA
Omada Health, Inc. Common Stock
$14.82
-9.63%
HEALTHCARE · Cap: $974.41M
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 23127% more annual revenue ($60.44B vs $260.21M). AZN leads profitability with a 17.2% profit margin vs -4.9%. AZN earns a higher WallStSmart Score of 62/100 (C+).
AZN
Buy62
out of 100
Grade: C+
OMDA
Hold37
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+6.6%
Fair Value
$220.34
Current Price
$182.85
$37.49 discount
Margin of Safety
+41.8%
Fair Value
$18.79
Current Price
$14.82
$3.97 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 24 in profit
Strong operational efficiency at 28.2%
Generating 1.8B in free cash flow
Revenue surging 58.1% year-over-year
Areas to Watch
Expensive relative to growth rate
Moderate valuation
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
Operating margin of 4.3%
ROE of -8.7% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.2% and operating margin at 28.2%. Revenue growth of 12.5% demonstrates continued momentum.
Bull Case : OMDA
The strongest argument for OMDA centers on Revenue Growth. Revenue growth of 58.1% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are PEG Ratio, P/E Ratio, Altman Z-Score.
Bear Case : OMDA
The primary concerns for OMDA are EPS Growth, Market Cap, Operating Margin.
Key Dynamics to Monitor
AZN profiles as a mature stock while OMDA is a hypergrowth play — different risk/reward profiles.
OMDA is growing revenue faster at 58.1% — sustainability is the question.
AZN generates stronger free cash flow (1.8B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
AZN scores higher overall (62/100 vs 37/100), backed by strong 17.2% margins and 12.5% revenue growth. OMDA offers better value entry with a 41.8% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Omada Health, Inc. Common Stock
HEALTHCARE · HEALTH INFORMATION SERVICES · USA
Omada Health, Inc. provides a range of virtual care programs in the United States. The company is headquartered in San Francisco, California.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?